Center for Clinical and Translational Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
Division of Pediatric Hematology/Oncology/Blood & Marrow Transplantation, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio.
Clin J Am Soc Nephrol. 2023 Feb 1;18(2):234-244. doi: 10.2215/CJN.0000000000000047.
Nephrotic syndrome is associated with an acquired hypercoagulopathy that is thought to drive its predisposition for venous thromboembolism. Previous studies have suggested that urinary antithrombin (AT) loss leading to acquired AT deficiency is the primary mechanism underlying this hypercoagulopathy, but this hypothesis has not been directly tested. The objectives of this study were to test the influence of AT levels on hypercoagulopathy in nephrotic syndrome patient samples and perform meta-analyses to evaluate the likelihood of AT deficiency in patients with nephrotic syndrome.
Samples from three independent nephrotic syndrome cohorts were analyzed. AT antigen and activity assays were performed using ELISA and amidolytic assays, respectively. Plasma thrombin generation, albumin, and urine protein-to-creatinine ratios were determined using established methods. Meta-analyses were performed by combining these new data with previously published data.
AT levels were not consistently related to either plasma albumin or proteinuria. AT was quantitatively related to hypercoagulopathy in adult nephrotic syndrome, whereas AT activity was inconsistently associated with hypercoagulopathy in childhood nephrotic syndrome. Notably, hypercoagulopathy did not differ between patients with normal AT levels and those with levels below the threshold used to define clinical AT deficiency (<70%). Moreover, ex vivo AT supplementation did not significantly alter hypercoagulopathy in AT-deficient plasma samples. The meta-analyses demonstrated that AT deficiency was not a uniform feature of nephrotic syndrome and was more common in children than adults.
These data suggest that AT deficiency plays only a limited role in the mechanisms underlying the acquired hypercoagulopathy of nephrotic syndrome. Moreover, AT deficiency was not present in all patients with nephrotic syndrome and was more likely in children than adults despite the higher risk for venous thromboembolism in adults than children.
肾病综合征与获得性高凝状态有关,后者被认为是其易发生静脉血栓栓塞的原因。先前的研究表明,尿抗凝血酶(AT)丢失导致获得性 AT 缺乏是这种高凝状态的主要机制,但这一假说尚未得到直接验证。本研究的目的是检测 AT 水平对肾病综合征患者样本中高凝状态的影响,并进行荟萃分析以评估肾病综合征患者 AT 缺乏的可能性。
分析了三个独立的肾病综合征队列的样本。使用 ELISA 和 amidolytic 测定法分别进行 AT 抗原和活性测定。使用既定方法测定血浆凝血酶生成、白蛋白和尿蛋白与肌酐比值。通过将这些新数据与先前发表的数据相结合,进行荟萃分析。
AT 水平与血浆白蛋白或蛋白尿均无一致关系。AT 与成人肾病综合征的高凝状态呈定量相关,而 AT 活性与儿童肾病综合征的高凝状态不一致相关。值得注意的是,AT 水平正常的患者与低于定义临床 AT 缺乏(<70%)阈值的患者之间的高凝状态没有差异。此外,体外 AT 补充并未显著改变 AT 缺乏的血浆样本中的高凝状态。荟萃分析表明,AT 缺乏不是肾病综合征高凝状态的普遍特征,且在儿童中比在成人中更为常见。
这些数据表明,AT 缺乏在肾病综合征获得性高凝状态的机制中仅起有限作用。此外,并非所有肾病综合征患者均存在 AT 缺乏,且在儿童中比在成人中更为常见,尽管成人比儿童的静脉血栓栓塞风险更高。